JeNaCell develops and manufactures biotechnologically produced nanocellulose using continuous production processes. Its bio-material is targeted at applications in medicine and cosmetics — for example interactive wound dressings and moisturizing face masks — as well as technology and pharmaceutical products. The company was spun off from Friedrich Schiller University in 2012 and is led by Dr. Nadine Hessler and Dr. Dana Kralisch, operating from Jena, Germany. JeNaCell recently completed a Series A financing of undisclosed amount. Investors in the round include Evonik Industries, bm-t beteiligungsmanagement thüringen GmbH, Sparkasse Jena, High-Tech Gründerfonds and the Foundation for Technology, Innovation and Research of Thuringia. The company intends to use the proceeds to expand production capacity and extend its distribution network. JeNaCell develops a high-performance biomaterial with natural nanostructures for use in medical, cosmetic and technology applications. The company’s technology is based on a new, patented process for the continuous production of the biomaterial. JeNaCell is a spin-off of Friedrich Schiller University in Jena and is led by CEO Dr. Nadine Hessler. The firm raised €700K in seed funding to support product optimization, the build-out of an automated production facility, and preparatory measures for market introduction. Backers include High‑Tech Gründerfonds and STIFT.

Total raised

$1M

Funding rounds

2

Latest round

Seed

Latest activity

Oct 2012